Dr Megan Smith

Megan Smith

Senior Research Fellow
E: megan.smith@nswcc.org.au

Research summary

Dr Megan Smith is a lead researcher in the Pathways–Cervical Cancer and HPV Group. Her research focuses on optimising and successfully implementing cervical cancer prevention, at the population level and in different population subgroups. Dr Smith has contributed to a large number of reports to government, including several evaluations that have directly informed policy in Australia, New Zealand and England, and is a member of multiple national or state-level committees/ advisory groups related to cervical cancer prevention.

Qualifications

PhD, The University of Sydney
MPH, The University of Sydney
BE, The University of Sydney

Grants

  • Optimising and Successfully Implementing Cervical Cancer Prevention Policies, Early Career Fellowship, NHMRC
  • Optimising and Successfully Implementing Cervical Cancer Prevention Policies, Early Career Fellowship, Cancer Institute NSW 
  • HPV Testing Modelling, Analysis and Review of NCSP Data (2016-2019), Project Grant, New Zealand Ministry of Health
  • HPV and oropharyngeal cancer in Indigenous Australians, Project Grant, NHMRC
  • Comparative modelling to inform cervical cancer control policies – CISNET Cervix, Program Grant, US National Institutes of Health (NIH)
  • Implementing Safety Monitoring of the National Cervical Screening Program, Australian Government Department of Health.

Academic affiliations 

Honorary Senior Research Fellow, School of Public Health, University of Sydney 

Current student supervision 

Susan Yuill, PhD candidate, School of Public Health, University of Sydney 

Selected key publications

Smith MA, Hall M, Lew J-B, Canfell K.  Potential for HPV vaccination and primary HPV screening to reduce cervical cancer disparities: example from New Zealand.  Vaccine 2018; 36(42):6314-6324. doi: 10.1016/j.vaccine.2018.08.063 

Burger EA*, Smith MA*, Killen J, Sy S, Simms K, Canfell K, Kim JJ. (* Joint first authors) Projected time to elimination of cervical cancer in the USA: a comparative modelling study. Lancet Public Health 2020. doi: 10.1016/S2468-2667(20)30006-2 

Simms K*, Hanley S*, Smith MA*, Canfell K, Keane A. (* Joint first authors) Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study. Lancet Public Health 2020. doi: 10.1016/S2468-2667(20)30010-4 

Smith MA, Hammond IG, Saville M. Lessons from the renewal of the National Cervical Screening Program in Australia. Public Health Res Pract 2019;29(2):e2921914  doi: 10.17061/phrp2921914 

Simms K, Steinberg J, Caruana M, Smith M, Lew JB, Castle P, Soerjomataram I, Bray F, Canfell K    Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study. Lancet Oncol 2019; 20(3): 394-407. doi: 10.1016/S1470-2045(18)30836-2 

Canfell K, Kim JJ, Brisson M, Keane A, Simms KT, Caruana M, Burger EA, Martin D, Nguyen DTN, Benard E, Sy S, Regan C, Drolet M, Gingras G, Laprise JF, Torode J, Smith MA, Fidarova E, Trapani D, Bray F, Ilbawi A, Broutet N, Hutubessy R. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet 2020; 395(10224):591-603. doi: 10.1016/s0140-6736(20)30157-4 

Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, Martin D, Simms KT, Benard E, Boilly MC, Sy S, Regan C, Keane A, Caruana M, Nguyen DTN, Smith MA, Laprise JF, Jit M, Alary M, Bray F, Fidarova E, Elsheikh F, Bloem PJN, Broutet N, Hutubessy R. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet 2020;395(10224):575-90. doi: 10.1016/S0140-6736(20)30068-4 

Lew JB*, Simms K,* Smith MA, Hall M, Kang YK, Xu X, Caruana M, Velentzis LS, Bessell T, Saville M, Hammond I and Canfell K. (*Joint first authors)   Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.  Lancet Public Health 2017; 2:e96-107. doi: 10.1016/S2468-2667(17)30007-5. 

Smith M, Lew JB, Simms K, Canfell K.  Impact of HPV sample self-collection for underscreened women in the renewed National Cervical Screening Program. MJA 2016; 204(5):194e1-e9. doi: 10.5694/mja15.00912. 

Smith M, Canfell K. Impact of the Australian National Cervical Screening Program in women of different ages. Med J Aust. 2016;205(8):359-64. doi: 10.5694/mja16.00289. 

Smith MA, Gertig D, Hall M, Simms K, Lew JB, Malloy M, Saville M, Canfell K.  Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use.  BMC Health Serv Res. 2016;16(1):147. doi: 10.1186/s12913-016-1375-9. 

Smith M, Liu B, McIntyre P, Menzies R, Dey A, Canfell K.  Fall in genital warts diagnoses in the general and Indigenous Australian population following a national HPV vaccination program: analysis of routinely collected national hospital data.  J Infect Dis 2015; 211(1):91-9. doi: 10.1093/infdis/jiu370.

More publications by Megan Smith

 

COVID-19 and cancer: What's your experience?

We are conducting a study about the impact of COVID-19 on people affected by cancer and healthcare workers in Australia.

Please click below to find out more and complete our short online survey (approx. 15 mins).

Find out more